Want to see BCDA full AI Analyst Report?
BCDA Stock Chart & Stats
$1.19
-$0.04(-4.92%)
At close: 4:00 PM EDT
$1.19
-$0.04(-4.92%)
Day’s Range― - ―
52-Week Range$0.75 - $2.29
Previous Close$0.82
Volume275.31K
Average Volume (3M)233.97K
Market Cap
$16.80M
Enterprise Value$11.17
Total Cash (Recent Filing)$4.12M
Total Debt (Recent Filing)$293.00K
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Nov 11, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding15,138,782
10 Day Avg. Volume203,554
30 Day Avg. Volume233,965
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.12
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.00Price Target Upside2000.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.68
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Japan Regulatory PathwayPMDA support creates a defined route toward potential commercialization in Japan. The sizeable target population and planned submission provide a concrete market-entry opportunity if remaining documentation and approval requirements are completed.
FDA And Helix Regulatory ProgressA potentially sufficient confirmatory trial could streamline the U.S. pathway for CardiAMP. Helix’s clinical experience and regulatory progress also strengthen BioCardia’s delivery platform and its ability to support future therapy partnerships.
Improved Cost Control And RunwayLower operating and R&D expenses improve capital efficiency and extend the time available to reach clinical and regulatory milestones. The reported cash runway reduces immediate funding pressure, although commercialization remains unproven.
Bears Say
No Meaningful RevenueBioCardia has not established a recurring commercial revenue base, leaving its prospects dependent on successful clinical development and future approvals. Continued losses also limit internal funding capacity and make financial performance highly binary.
Persistent Cash Burn And Dilution RiskSustained negative cash generation means BioCardia must rely on financing or remaining cash to fund development. Further equity raises could dilute shareholders, while constrained resources may slow progress toward regulatory and commercial milestones.
Slow Trial Execution And Regulatory UncertaintyLimited enrollment can delay the confirmatory program and defer potential U.S. commercialization. Additional regulator requests and unresolved endpoint issues add execution risk, increasing the time and capital required before CardiAMP can generate durable revenue.
BioCardia News
BCDA FAQ
What was BioCardia Inc’s price range in the past 12 months?
BioCardia Inc lowest stock price was $0.75 and its highest was $2.29 in the past 12 months.
What is BioCardia Inc’s market cap?
BioCardia Inc’s market cap is $16.80M.
When is BioCardia Inc’s upcoming earnings report date?
BioCardia Inc’s upcoming earnings report date is Nov 11, 2026 which is in 67 days.
How were BioCardia Inc’s earnings last quarter?
BioCardia Inc released its earnings results on Aug 12, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.05.
Is BioCardia Inc overvalued?
According to Wall Street analysts BioCardia Inc’s price is currently Undervalued.
Does BioCardia Inc pay dividends?
BioCardia Inc does not currently pay dividends.
What is BioCardia Inc’s EPS estimate?
BioCardia Inc’s EPS estimate is -0.13.
How many shares outstanding does BioCardia Inc have?
BioCardia Inc has 15,138,782 shares outstanding.
What happened to BioCardia Inc’s price movement after its last earnings report?
BioCardia Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went up 5.455%.
Which hedge fund is a major shareholder of BioCardia Inc?
Currently, no hedge funds are holding shares in BCDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioCardia Inc
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
BCDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful regulatory progress across Japan (PMDA) and the U.S. (FDA) and favorable feedback for the HELIX catheter, supported by substantial clinical experience (~500 Helix patients, >20x procedural experience vs peers). Financially, the company improved expense control and narrowed net losses, and raised ~$4.9M, leaving cash into 2027. Key challenges include additional PMDA documentation requests, relatively slow enrollment in the U.S. confirmatory trial that is resource-constrained, tight near-term financing needs to accelerate enrollment, and some regulatory process uncertainties (FDA minutes delay, endpoint discussions, reimbursement timing). On balance, positives (regulatory momentum, commercialization pathway in Japan, improved financial trends) materially outweigh the operational and cash runway challenges, though execution risk remains.View all BCDA earnings summariesBCDA Stock 12 Month Forecast
Average Price Target
$25.00
▲(2000.84% Upside)
Technical Analysis
Pluri
―
Celularity
―
Revelation Biosciences
―
SeaStar Medical Holding
―
Cardio Diagnostics Holdings
―
Ownership Overview
14.44% Insiders
1.24% Mutual Funds
2.92% Other Institutional Investors
80.58% Public Companies and
Individual Investors